nivolumab,bempegaldesleukin,ipilimumab,cabozantinib
bms,nektar,exelixis
['nivo', 'bempeg', 'triplet,(-triplete)', 'nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'renal,(-adrenal)']
in advanced, untreated renal cell carcinoma (#rcc), a tki-immunotherapy triplet improved pfs, but bempeg plus nivolumab numerically worsened objective response rate. #esmo22 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.